Literature DB >> 11138474

[Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma].

B Gasztonyi1, A Pár, A Szomor, A Nagy, L Kereskai, H Losonczy, L Pajor, M Horanyi, G Mózsik.   

Abstract

Oncogenesis is a multifactorial process in which environmental, genetical and infectious factors may be of importance. Specific viruses are supposed to have etiological role in about 15% of human tumors. Recently the B-cell proliferation inducing effect of the hepatotropic and lymphotropic hepatitis-C virus (HCV) came into the limelight based on the high prevalence of HCV positivity in B-cell non-Hodgkin's lymphoma (NHL) patients. The aim of the authors was to establish the prevalence of HCV infection in NHL patients. Paralelly the HBV, CMV and EBV markers, and the alterations of the humoral immune response (immunoglobulins, cryoglobulins, rheumatoid factor) were determined. 42 patients (24 male, 18 female; the mean age: 54.1 years, range 22-80 years) classified as 16 indolent (low risk), and 25 aggressive (intermediate risk) NHL and one with very aggressive Burkitt's lymphoma, according to the modified REAL classification were examined. Enzyme-linked immunosorbent assay (ELISA) for HBsAg and anti-HCV, HBsAg, anti EBV, anti CMV, furthermore polymerase chain reaction (PCR) for HCV-RNA were used. Anti-HCV was found in 6/42 NHL patients (14.3%), while anti-HCV and/or HCV-RNA PCR positivity revealed on overall HCV infection in 10/42 (23.8%) patients. None of them were HBsAg positive. Our findings support the hypothesis, that HCV might have an aetiological role in the lymphoproliferation leading to B-cell NHL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11138474

Source DB:  PubMed          Journal:  Orv Hetil        ISSN: 0030-6002            Impact factor:   0.540


  1 in total

1.  Development of multiple myeloma in a patient with chronic hepatitis C: A case report and review of the literature.

Authors:  Peter Laszlo Lakatos; Sandor Fekete; Margit Horanyi; Simon Fischer; Margit E Abonyi
Journal:  World J Gastroenterol       Date:  2006-04-14       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.